Neuroscientific Biopharmaceuticals Ltd (ASX:NSB)
NeuroScientific Biopharmaceuticals Ltd is an Australia-based company, which develops peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with unmet medical demand. The company’s product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn), which have demonstrated similar therapeutic potential as EmtinB. EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinBTM is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body’s innate immune response to cell injury.